Detailed Analysis
A small healthcare business's attempt to obtain enterprise AI quotes from three major vendors — OpenAI, Google, and Anthropic — reveals a striking disparity in how AI companies approach the sales process for regulated industries. OpenAI responded quickly with a quote, Google initiated a prolonged series of meetings, and Anthropic, two months into the process, had still not connected the prospective customer with a live sales representative. The experience, documented at ap7i.com, is particularly notable because the business required a HIPAA Business Associate Agreement (BAA), a standard compliance requirement for any vendor handling protected health information — a use case that sits squarely within the high-value enterprise segments all three companies publicly claim to serve.
Anthropic's difficulty in closing even initial sales contact reflects structural realities of how Claude Enterprise is sold. The product has no published flat-rate pricing and requires direct engagement with a sales team for custom quotes. Anecdotal figures suggest costs around $60 per seat with a minimum commitment of roughly 70 users on 12-month contracts. Anthropic also recently restructured its pricing model away from fixed per-seat subscriptions toward a hybrid arrangement combining lower base fees with mandatory upfront consumption commitments — a shift that removes the predictability smaller organizations depend on when evaluating vendor relationships. For a healthcare SMB trying to assess total cost of ownership while also navigating HIPAA compliance requirements, the inability to even reach a sales contact within a two-month window is a significant practical barrier, regardless of the underlying product quality.
The broader context illuminates why Anthropic's sales motion appears selectively accessible. The company's own enterprise guidance acknowledges that successful adoption requires executive buy-in, data infrastructure investment, and specialized talent — obstacles cited by 62% of C-suite respondents in its research. Early Claude Enterprise adoption has concentrated heavily (77% of usage) in high-value automation scenarios at well-resourced organizations, suggesting Anthropic's go-to-market approach is implicitly calibrated toward large enterprises with mature AI readiness rather than the SMB market. Compute constraints introduced since mid-2025, including GPU quotas, rolling rate limits, and weekly caps driven by the intensive demands of agentic workflows, further reinforce a posture of managed scarcity that disadvantages smaller or more experimental buyers.
The competitive contrast is instructive. OpenAI's rapid quote response signals a more transactional, self-service-oriented sales culture, while Google's meeting-heavy process at least keeps the prospective customer engaged in an active pipeline. Anthropic's apparent absence from the conversation entirely points to either an understaffed sales organization relative to inbound demand, a deliberate strategy of deprioritizing SMB accounts, or both. For a company that has positioned Claude as a safety-conscious, enterprise-grade alternative to competitors, failing to operationalize that positioning at the sales stage represents a gap between brand messaging and commercial execution. Healthcare SMBs represent a non-trivial addressable market with genuine willingness to pay for compliant AI tooling, and the inability to meet them at first contact cedes that ground to faster-moving rivals.
This episode connects to a recurring tension in the enterprise AI market between the rapid commoditization of AI capabilities and the uneven maturity of AI vendors as sales organizations. As foundation model performance converges across leading providers, procurement experience, responsiveness, compliance infrastructure, and pricing transparency increasingly become differentiating factors. Anthropic's research pedigree and model quality have earned it significant enterprise credibility, but credibility does not automatically translate into accessible commercial relationships. The company's shift to hybrid consumption-based pricing, while potentially advantageous for large and predictable workloads, introduces complexity that demands more — not less — hands-on sales support to explain and justify. Until Anthropic closes the gap between its product ambitions and its sales capacity, particularly for regulated-industry customers navigating compliance requirements alongside procurement timelines, it risks losing to competitors who are simply easier to buy from.
Read original article →